ScreenerHero

LAVI Lavipharm S.A.

ATH · GR · Healthcare · Drug Manufacturers - Specialty & Generic · lavipharm.com
1.530EUR0.00%Mkt Cap: 284.01M $P/E: 51.00

Lavipharm S.A. engages in the research, development, manufacture, import, marketing, sale, and wholesale of pharmaceutical, cosmetics, and healthcare products to physicians and pharmacists in Greece and internationally. …

Industry Peers

Drug Manufacturers - Specialty & Generic
Screen all
MRK
Merck KGaA
$66.23BUSDP/E 25.7
TAK
Takeda Pharmaceutical Company Limited
$58.68BUSD
TEVA
Teva Pharmaceutical Industries Limited
$45.70BUSDP/E 65.3
GALD
Galderma Group AG
$43.27BUSDP/E 56.1
HLN
Haleon plc
$39.67BUSDP/E 18.4
SDZ
Sandoz Group AG
$34.93BUSDP/E 60.5
HLN
Haleon plc
$32.73BUSDP/E 19.0
ZTS
Zoetis Inc.
$29.57BUSDP/E 11.8
ZOE
Zoetis Inc.
$28.56BUSDP/E 12.2
UTHR
United Therapeutics Corporation
$23.38BUSDP/E 19.5
VTRS
Viatris Inc.
$20.09BUSD
SOBI
Swedish Orphan Biovitrum AB (publ)
$14.43BUSDP/E 112.9
NBIX
Neurocrine Biosciences, Inc.
$14.58BUSDP/E 21.0
IPN
Ipsen S.A.
$12.99BUSDP/E 23.5
ELAN
Elanco Animal Health Incorporated
$11.17BUSD
RDY
Dr. Reddy's Laboratories Limited
$10.22BUSDP/E 27.9
KRK
Krka, d. d.
$8.66BUSDP/E 19.3
ALKS
Alkermes plc
$6.95BUSDP/E 109.1
HIMS
Hims & Hers Health, Inc.
$6.89BUSD
AMRX
Amneal Pharmaceuticals, Inc.
$6.84BUSDP/E 40.1

Key Statistics

Company
Market Cap284.01M USD
Enterprise Value330.51M USD
Revenue (TTM)76.43M USD
Gross Profit32.94M USD
Net Income (TTM)6.51M USD
Revenue/Share0.42 EUR
Last Price1.530 EUR
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees306
CountryGR
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
ISINGRS246003008
Valuation
P/E (Trailing)51.00
P/E (Forward)—
PEG—
EV/EBITDA22.71
EV/Revenue4.32
P/S3.79
P/B4.73
EPS (TTM)0.03
EPS (Forward)—
52W Range
0.756079% of range1.734
52W High1.734 EUR
52W Low0.7560 EUR
Profitability
Gross Margin48.42%
Oper. Margin13.63%
EBITDA Margin19.04%
Profit Margin9.56%
ROE10.61%
ROA4.60%
Growth
Revenue Growth41.30%
Earnings Growth54.50%
Cash Flow & Leverage
Operating CF7.25M USD
CapEx (TTM)5.02M USD
FCF Margin-13.59%
FCF Yield-3.66%
Net Debt40.93M USD
Net Debt/EBITDA2.81
Balance Sheet
Debt/Equity0.58
Current Ratio1.22
Quick Ratio0.58
Book Value/Sh0.33 EUR
Cash/Share0.02 EUR
Dividends
Fwd Div Rate0.02 EUR
Trail. Div Rate0.02 EUR
Div. Yield1.28%
5Y Avg Yield3.13%
Payout Ratio68.49%
Ex-Div DateJul 20, 2026
Pay DateNov 8, 1995
Splits
Last Split1:3
Split DateAug 1, 2022
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.170.78M
Float—
Insiders61.09%
Institutions1.22%
Technical
SMA 501.588 (-3.7%)
SMA 2001.412 (+8.3%)
Beta1.01
S&P 52W Chg16.45%
Avg Vol (30d)89.95K
Avg Vol (10d)101.01K
Technical Indicators
RSI (14)37.7
MACD-0.0097
MACD Signal-0.0050
MACD Hist.-0.0047
BB Upper1.613 EUR
BB Middle1.573 EUR
BB Lower1.534 EUR
BB Width5.01%
ATR (14)0.0404 EUR
Vol Ratio (20d)2.15x